Literature DB >> 1912372

Enhancing effect of ubenimex (bestatin) on proliferation and differentiation of hematopoietic progenitor cells, and the suppressive effect on proliferation of leukemic cell lines via peptidase regulation.

K Shibuya1, S Chiba, M Hino, T Kitamura, K Miyagawa, F Takaku, K Miyazano.   

Abstract

Ubenimex (Bestatin) significantly enhanced the G- and GM-CSF-induced colony formation of human bone marrow cells at concentrations of 0.001, 0.01, 0.1 and 1.0 microgram/ml (21-61% enhancement), but not at 10 micrograms/ml. Ubenimex did not influence the EPO-induced erythroid colony and burst formation between 0.0001-100 micrograms/ml. Against human and mouse leukemic cell lines, the growth-inhibitory activities of ubenimex were dose-dependently observed. Aminopeptidase activities on U937 and TF-1 cells were almost inhibited with 10 and 100 micrograms/ml of ubenimex, respectively. Cross-linking studies of 125I-GM-CSF binding to TF-1 cells demonstrated that the 150-kDa band of 2 major bands was enhanced after incubation with 0.01 microgram/ml ubenimex but decreased after that with 100 micrograms/ml, and that the 95-kDa band was not changed at any concentration of ubenimex. Change in density of the 150-kDa band on ubenimex-treated TF-1 cells was correlated with that in expression of CD10 (neutral endopeptidase) on them, whereas that in expression of CD13 (aminopeptidase N) was not changed at any concentration. These results suggest that one possible mechanism of ubenimex action in hematopoietic progenitor cells is the up-regulation of the high affinity receptor for GM-CSF and that in leukemic cell lines is suppression of amino acid incorporation via peptidase regulation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1912372     DOI: 10.1016/0753-3322(91)90125-d

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  Heterologous expression and purification of Vibrio proteolyticus (Aeromonas proteolytica) aminopeptidase: a rapid protocol.

Authors:  Mariam Hartley; Wei Yong; Brian Bennett
Journal:  Protein Expr Purif       Date:  2009-02-20       Impact factor: 1.650

2.  Ubenimex in the treatment of acute nonlymphocytic leukemia in adults.

Authors:  A Urabe; Y Mutoh; H Mizoguchi; F Takaku; N Ogawa
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

3.  Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions.

Authors:  Mirjana Grujić; Metka Renko
Journal:  Cancer Lett       Date:  2002-08-28       Impact factor: 8.679

Review 4.  Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

Authors:  Brigitte Bauvois; Daniel Dauzonne
Journal:  Med Res Rev       Date:  2006-01       Impact factor: 12.944

5.  Expression of aminopeptidase N on human choriocarcinoma cells and cell growth suppression by the inhibition of aminopeptidase N activity.

Authors:  K Ino; S Goto; T Okamoto; S Nomura; A Nawa; K Isobe; S Mizutani; Y Tomoda
Journal:  Jpn J Cancer Res       Date:  1994-09

6.  Ubenimex activates the E-cadherin-mediated adhesion of a breast cancer cell line YMB-S.

Authors:  S Fujioka; N Kohno; K Hiwada
Journal:  Jpn J Cancer Res       Date:  1995-04

Review 7.  The significance of aminopeptidases and haematopoietic cell differentiation.

Authors:  K Razak; A C Newland
Journal:  Blood Rev       Date:  1992-12       Impact factor: 8.250

8.  Inhibitory effect of the oral immune response modifier, bestatin, on cell-mediated and cell-free HIV infection in vitro.

Authors:  A S Bourinbaiar; S Lee-Huang; K Krasinski; W Borkowsky
Journal:  Biomed Pharmacother       Date:  1994       Impact factor: 6.529

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.